^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review

Published date:
12/29/2023
Excerpt:
The first case included a 38-year-old female who had an EGFR ex20ins mutation (p.S768_D770dupSVD). After 1 month of treatment with furmonertinib, her symptoms of pain and cough were significantly alleviated. She achieved a partial response according to response evaluation criteria in solid tumors. The final progression-free survival was 8.13 months.
DOI:
10.1097/MD.0000000000036667